ArticleVaccine2020
A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Efficient Production of Swine Influenza Virus Using Serum-Free Suspension MDCK Cells for Vaccine Manufacturing.Journal of microbiology and biotechnology · 2026Article
- Polymeric rumen-stable delivery systems for delivering nutricines.Open veterinary journal · 2025Review
- Feline immunodeficiency virus: current insights into pathogenesis, clinical impact, and advances in treatment and vaccine development.Frontiers in veterinary science · 2025Review
- The safety of overdose and repeat administrations of BCG Danish strain 1331 vaccine in calves and pregnant heifers.Heliyon · 2024Article
- Commercial vaccines used in poultry, cattle, and aquaculture: a multidirectional comparison.Frontiers in veterinary science · 2023Article
- The safety of BCG vaccination in cattle: results from good laboratory practice safety studies in calves and lactating cows.Heliyon · 2022Article
- Caecal microbiota composition of experimental inbred MHC-B lines infected with IBV differs according to genetics and vaccination.Scientific reports · 2022Article
- Technology Readiness Levels for vaccine and drug development in animal health: From discovery to life cycle management.Frontiers in veterinary science · 2022Article
- Using cross-species vaccination approaches to counter emerging infectious diseases.Nature reviews. Immunology · 2021Review
- From Bench to Field: A Guide to Formulating and Evaluating Anti-Tick Vaccines Delving beyond Efficacy to Effectiveness.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The UK Government recognised the importance of vaccines in the control of new emerging disease threats and in 2015 established the UK Vaccine Network to focus on specific areas of need. One of these was the understanding of what is involved in the development of a new vaccine and what are the potential bottlenecks to a rapid response in the face of an epidemic such as Ebola, MERS and more recently COVID-19. A Working Group was established to initially produce a Vaccine Development Process Map for a Human Vaccine. However, in view of the importance of animal wellbeing and the significant impact of diseases with Zoonotic potential, a similar Map has been created outlining the Veterinary Vaccine Development Process. This paper describes the production of that Map and covers the process from the generation of a Target Product Profile (TPP) through Discovery and Feasibility, and on to Product Development and Registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.